175 related articles for article (PubMed ID: 17550851)
21. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia.
Gómez-Almaguer D; Jaime-Pérez JC; Garza-Rodríguez V; Chapa-Rodríguez A; Tarín-Arzaga L; Herrera-Garza JL; Ruiz-Argüelles GJ; López-Otero A; González-Llano O; Rodríguez-Romo L
Ann Hematol; 2010 Mar; 89(3):299-303. PubMed ID: 19705116
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival.
Juliusson G; Theorin N; Karlsson K; Frödin U; Malm C
Bone Marrow Transplant; 2006 Mar; 37(5):503-10. PubMed ID: 16415894
[TBL] [Abstract][Full Text] [Related]
25. Thymopentin in Sézary syndrome.
Bernengo MG; Appino A; Bertero M; Novelli M; Fierro MT; Doveil GC; Lisa F
J Natl Cancer Inst; 1992 Sep; 84(17):1341-6. PubMed ID: 1386633
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
27. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
28. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
Zinzani PL; Alinari L; Tani M; Fina M; Pileri S; Baccarani M
Haematologica; 2005 May; 90(5):702-3. PubMed ID: 15921394
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
30. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
[No Abstract] [Full Text] [Related]
31. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
[TBL] [Abstract][Full Text] [Related]
32. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
33. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy.
Moccia A; Ghielmini M
Semin Hematol; 2008 Apr; 45(2):75-84. PubMed ID: 18381101
[TBL] [Abstract][Full Text] [Related]
35. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
Enblad G; Hagberg H; Erlanson M; Lundin J; MacDonald AP; Repp R; Schetelig J; Seipelt G; Osterborg A
Blood; 2004 Apr; 103(8):2920-4. PubMed ID: 15070664
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
Buckstein R; Fraser G; Cheung M; Kukreti V; Kuruvilla J; Imrie K; Piliotis E; Pond G; Windsor J; Ghorab Z; Shuoprasad K; Turner R; Meyer RM; Pritchard K; Walker S; Levine M; Crump M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):18-28.e4. PubMed ID: 26711181
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
[No Abstract] [Full Text] [Related]
40. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
